Pharmaceutical Industry Information Portal


All posts by tag


Vladimir Khristenko resigns as President of Nanolek

Co-founder of Nanolek Vladimir Khristenko announced his intention to step down as President, the post he has been holding since 2015. Mr. Khristenko transferred...

NANOLEK began industrial production of the CoviVac vaccine

NANOLEK announced the launch of industrial production of CoviVac. Investments in this project amounted to 40 million rubles, the company said. The manufacturer plans...

All the four national vaccines are produced rhythmically in line with the plans

Russia has put into circulation about 32 million sets of coronavirus vaccines since the beginning of the year, and new sites are joining in...

Positive results were obtained for the drug Zanubrutinib in a comparative trial with Isrutinib

Brukinsa® (zanubrutinib) is under regulatory review for relapsed, refractory MCL in the Russian Federation with potential approval at the end of the 2021.

NANOLEK will invest 5 billion rubles in the full production cycle

Nanolek, a biopharmaceutical company, announces a plan to invest 5 billion rubles over 3 years in its full-cycle vaccine production facility in the Kirov region and an R&D Center for Biotech Medicines in Moscow.

The plant of Nanolek is about to launch production of the third Covivac vaccine

Nanolek uses a traditional technology to produce this vaccine containing an inactivated virus that triggers a potent immune response.

Expert Articles